[1] Song F, Shi N, Shan F, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology 2020; 200274. DOI: 10.1148/radiol.2020200274.
[2] Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020. DOI: 10.1056/NEJMc2001737.
[3] Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 2020. DOI: 10.1007/s11684-020-0754-0.
[4] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727–733.
[5] Lu R, Zhao X, Li J, et al. Genome characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020. DOI: 10.1016/S0140-6736(20)30251-8.
[6] Cheng F. In silico oncology drug repositioning and polypharmacology. Methods Mol. Biol. 2019; 1878: 243–261.
[7] Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery 2020; 6: 14.
[8] Guo D. Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases. Virologica Sinica 2020. DOI: 10.1007/s12250-020-00204-7.
[9] Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature reviews: Drug Discovery 2020; 19: 149-150.
[10] Wang Y, Zhu LQ. Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019. World Journal of Pediatrics 2020. DOI: 10.1007/s12519-020-00353-5.
[11] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 2019–2021.
[12] Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends 2020; 14(1): 72-73.
[13] De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem. Asian J. 2019; 14: 3962–3968.
[14] Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science, 2020. DOI: 10.1126/science.abb3405.
[15] Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B 2020. https://doi.org/10.1016/j.apsb.2020.02.008.
[16] Hilgenfeld R. From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 2014; 281: 4085–4096.
[17] Mazumder MK, Borah A, Choudhury S. Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities. Medical Hypotheses 2020; 137: 109544.
[18] Mazumder MK, Choudhury S, Borah A. An in silico investigation on the inhibitory potential of the constituents of Pomegranate juice on antioxidant defense mechanism: relevance to neurodegenerative diseases. IBRO Rep 2019; 6: 153–159.
[19] Mazumder MK, Choudhury S. Tea polyphenols as multi-target therapeutics for Alzheimer’s disease: an in silico study. Med Hypotheses 2019; 125: 94–99.
[20] Mazumder MK, Paul R, Borah A. β-phenethylamine - a phenylalanine derivate in brain – Contributes to Oxidative Stress by Inhibiting Mitochondrial Complexes and DT-Diaphorase: An In Silico Study. CNS Neurosci Therap. 2013; 19(8): 596-602.
[21] Mazumder MK, Bhattacharya P, Borah A. Inhibition of matrix metalloproteinase-2 and 9 by Piroxicam confer neuroprotection in cerebral ischemia: an in silico evaluation of the hypothesis. Med Hypotheses 2014; 83: 697–701.
[22] Mazumder MK, Borah A. Piroxicam inhibits NMDA receptor-mediated excitotoxicity through allosteric inhibition of the GluN2B subunit: an in silico study elucidating a novel mechanism of action of the drug. Med Hypotheses 2014; 83: 740–746.
[23] Khan S, Siddique R, Shereen MA, et al. The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options. Journal of Clinical Microbiology 2020. DOI:10.1128/JCM.00187-20.
[24] Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opinion in Drug Discovery 2019; 14: 397–412.
[25] Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63(8): 769–802.
[26] Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003; 9: 399–406.
[27] Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59(3): 252–256.
[28] Chong YP, Song JY, Seo YB, et al. Antiviral treatment guidelines for Middle East respiratory syndrome. Infect Chemother 2015; 47: 212–222.
[29] Arabi YM, Asiri AY, Assiri AM, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020; 21(1): 8.
[30] Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 1997; 41(3): 654–660.
[31] Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1998; 42(12): 3218–3224.
[32] de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 2014; 58(8): 4875–4884.
[33] Choy KT, Yin-Lam Wong A, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Research 2020; 104786. DOI: 10.1016/j.antiviral.2020.104786.
[34] Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine 2020. DOI: 10.1056/NEJMoa2001282.
[35] Yan D, Liu X-y, Zhu Y-n, et al. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection. Medrexiv Preprint, 2020. doi: 10.1101/2020.03.22.20040832.
[36] Dahlén SE. Treatment of asthma with antileukotrienes: first line or last resort therapy? European Journal of Pharmacology 2006; 533(1–3): 40–56.
[37] He J, Hu XP, Zeng Y, et al. Advanced research on acteoside for chemistry and bioactivities. Journal of Asian Natural Products Research 2011; 13(5): 449–464.
[38] Yang J, Guoa J, Yuan J. In vitro antioxidant properties of rutin. LWT 2008; 41: 1060–1066.
[39] Patel K, Patel DK. The Beneficial Role of Rutin, A Naturally Occurring Flavonoid in Health Promotion and Disease Prevention: A Systematic Review and Update. Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases, 2019; 457–479. DOI: 10.1016/b978-0-12-813820-5.00026-x.
[40] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–513.
[41] Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. SSRN 2020. DOI: 10.2139/ssrn.3527420.
[42] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv Preprint 2020. DOI: 10.1101/2020.02.06.20020974.
[43] Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol 2019; 10: 50.
[44] Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virologica Sinica 2020. DOI: 10.1007/s12250-020-00207-4.
[45] Ni L, Zhou L, Zhou M, Zhao J, Wang DW. 2020. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan. Front Med. 2020. DOI: 10.1007/s11684-020-0757-x.